EOM 1352: Fri 7 June 2024, 11:36
Catalyst 7 July 2023, 14:52
Media Pack
News

Current Edition

Volume 16 Issue 4
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

Velabs to develop novel immune-based therapy for obesity

Announces strategic partnership with alytas therapeutics Velabs Therapeutics GmbH (Velabs), a biotech company focused on the rapid screening of functional therapeu...
5 September 2019 Europe | news | North America
Continue Reading →
Europe

IBD research smashes recruitment target two years early

by Anna Smith Cambridge University Hospital NHS Foundation Trust has announced that its inflammatory bowel disease (IBD) research has hit its recruitment target ...
5 September 2019 Europe | news | North America
Continue Reading →
Europe

Novartis announces positive results from two Entresto trials

by Anna Smith Novartis has announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto...
5 September 2019 Europe | news
Continue Reading →
Europe

NICE nod for Novartis’ Luxturna

by Anna Smith The National Institute for Health and Care Excellence (NICE) has recommended the use of Luxturna (voretigene neparvovec) on the NHS, Novartis has ann...
5 September 2019 Europe | news
Continue Reading →
news

FDA Urges Inclusion Of Men In Breast Cancer Clinical Trials

Men with breast cancer have significantly fewer treatment options than women with the disease, partly due to exclusion from many clinical trials. A new document f...
29 August 2019 news | North America | Regional News
Continue Reading →
news

FDA grants Fast Track designation for Farxiga in chronic kidney disease

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to dela...
29 August 2019 news | North America | Regional News
Continue Reading →
Europe

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure

AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint ...
29 August 2019 Europe | news | Regional News
Continue Reading →
news

Lilly’s case for Taltz helped by expanded approval

Credit: Eli Lilly & Co. Eli Lilly on Monday won an expanded approval for its psoriasis and arthritis drug Taltz, securing a Food and Drug Administration OK t...
29 August 2019 news | North America | Regional News
Continue Reading →
Europe

AstraZeneca’s Breztri scores in COPD trial, amping its case for triple-combo battle against GSK

Could "orphan drug" status for Fasenra and a Breztri trial win give AstraZeneca a leg up in its battle against GlaxoSmithKline? (AstraZeneca) AstraZeneca and Gla...
29 August 2019 Europe | news | North America | Regional News
Continue Reading →
news

Spurned by FDA a decade ago, Kyowa Kirin wins nod for Parkinson’s drug

Kyowa Kirin has won FDA nod for Nourianz as an add-on treatment to levodopa/carbidopa in adult Parkinson’s disease patients experiencing "off" episodes. (Pixabay/st...
29 August 2019 news | North America | Regional News
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Pharmap: Wed 13 November 2024, 10:36
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte